Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.
Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.
Comput Math Methods Med. 2023 Feb 7;2023:4164232. doi: 10.1155/2023/4164232. eCollection 2023.
The aim of this study was to explore cervical carcinoma and screen a suitable gene as the biomarker used for prognosis evaluation as well as pain therapy. Low expression levels of solute carrier family 24 member 3 (SLC24A3) was involved in the appearance and development of numerous malignancies. Nevertheless, the prognostic value of SLC24A3 expression with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients remains uncertain. During the present study, SLC24A3 expression in CESC was retrieved from TCGA, GEO, and MSigDB databases. Based on TCGA and GEO profiles, we performed survival and difference analyses about SLC24A3 both in two GEO (GSE44001 and GSE63514) and TCGA-CESC cohorts (all < 0.05), indicating that SLC24A3 was low expressed in tumors and associated with higher overall survival in CESC patients. Additionally, we programmed a series of analyses, including genomic profiling, enrichment analysis, immune infiltration analysis, and therapy-related analysis to identify the mechanism of the SLC24A3 in the process of cancer in CESC. Meanwhile, qRT-PCR was used to validate that the expression of SLC24A3 mRNA in Hela and SiHa cell lines was significantly lower than in PANC-1 and HUCEC cell lines. Our finding elucidated that the SLC24A3, a sodium-calcium regulator of cells, is an indispensable factor which can significantly influence the prognosis of patients with CESC and could provide novel clinical evidence to serve as a potential biological indicator for future diagnosis and pain therapy.
本研究旨在探讨宫颈癌，并筛选合适的基因作为预后评估和疼痛治疗的生物标志物。溶质载体家族 24 成员 3（SLC24A3）的低表达与许多恶性肿瘤的发生和发展有关。然而，SLC24A3 在宫颈鳞状细胞癌和宫颈内膜腺癌（CESC）患者中的表达的预后价值尚不确定。在本研究中，从 TCGA、GEO 和 MSigDB 数据库中检索到 SLC24A3 在 CESC 中的表达。基于 TCGA 和 GEO 图谱，我们对 TCGA-CESC 队列（均<0.05）中的两个 GEO（GSE44001 和 GSE63514）中的 SLC24A3 进行了生存和差异分析，结果表明 SLC24A3 在肿瘤中低表达，与 CESC 患者的总生存率较高相关。此外，我们进行了一系列分析，包括基因组分析、富集分析、免疫浸润分析和治疗相关分析，以确定 SLC24A3 在 CESC 癌症过程中的作用机制。同时，qRT-PCR 用于验证 SLC24A3 mRNA 在 Hela 和 SiHa 细胞系中的表达明显低于 PANC-1 和 HUCEC 细胞系。我们的研究结果表明，SLC24A3 作为细胞的钠钙调节剂，是一个不可或缺的因素，可显著影响 CESC 患者的预后，并为未来的诊断和疼痛治疗提供新的临床证据，作为潜在的生物学指标。
